Subject(s)
Brain Neoplasms/pathology , Lymphoma, Non-Hodgkin/pathology , Neoplasm Regression, Spontaneous/pathology , Aged , Autopsy , Fatal Outcome , Gait Disorders, Neurologic/diagnostic imaging , Gait Disorders, Neurologic/etiology , Gait Disorders, Neurologic/physiopathology , Humans , Magnetic Resonance Imaging , Male , Neurologic Examination , RadiographyABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Adult , Incidental Findings , Multiple Sclerosis/diagnosis , Demyelinating Diseases/diagnosis , Magnetic Resonance SpectroscopySubject(s)
Magnetic Resonance Imaging/methods , Multiple Sclerosis , Nerve Fibers, Myelinated , Adult , Female , Humans , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/etiology , Multiple Sclerosis/pathology , Nerve Fibers, Myelinated/diagnostic imaging , Nerve Fibers, Myelinated/pathology , Radiography , Risk Factors , Syndrome , Young AdultABSTRACT
Introducción y objetivos. Aunque la vía oral es la forma habitual de administración de los fármacos antiepilépticos, en ciertas ocasiones se requiere la vía parenteral. El levetiracetam es el único de los nuevos fármacos antiepilépticos con posibilidad de administración por vía intravenosa. Se presenta un estudio de utilización de levetiracetam intravenoso en un hospital general, con evaluación de su eficacia y seguridad. Pacientes y métodos. Se analizaron de forma retrospectiva las historias clínicas de todos los pacientes ingresados en el hospital que fueron tratados con levetiracetam intravenoso durante el período de tiempo comprendido entre julio de 2007 y mayo de 2008. Resultados. Un total de 53 pacientes fue tratado con levetiracetam intravenoso. Aproximadamente la mitad de los pacientes (47%) había estado ingresada a cargo del servicio de neurología, seguido del servicio de neurocirugía (21%) y oncología (9%). La edad media fue de 52,2 años (rango: 9-87 años) y el 40% eran mujeres. Las crisis fueron sintomáticas en el 81%, y las etiologías más frecuentes fueron los ictus (40%) y los tumores cerebrales (33%). La presentación clínica más frecuente fueron las crisis epilépticas repetidas (47,2%) y el estado epiléptico (26,4%). Globalmente, el control de las crisis se consiguió en el 87% de los pacientes. No se detectaron efectos adversos graves atribuibles al tratamiento con levetiracetam. Conclusiones. El levetiracetam intravenoso parece ser un fármaco antiepiléptico eficaz y seguro en pacientes hospitalizados, especialmente en aquéllos que presentan comorbilidad asociada y/o plurimedicación (AU)
Introduction and aims. Although antiepileptic drugs are usually administered orally, sometimes they must be given intravenously. Levetiracetam is the only one of the new antiepileptic drugs that can be administered intravenously. In this study we report on the use of intravenous levetiracetam in a general hospital, while also evaluating its effectiveness and safety. Patients and methods. A retrospective analysis was conducted of the medical records of all hospital admissions that were treated with intravenous levetiracetam between July 2007 and May 2008. Results. A total of 53 patients were treated with intravenous levetiracetam. Approximately half the patients (47%) had been admitted to neurology, followed by neurosurgery (21%) and oncology (9%). The mean age was 52.2 years (range: 9-87 years) and 40% were females. Seizures were symptomatic in 81% of cases and the most common aetiologies were strokes (40%) and brain tumours (33%). The most frequent presenting symptoms were repeated epileptic seizures (47.2%) and epileptic status (26.4%). Overall, control of seizures was achieved in 87% of patients. No severe side-effects that could be attributed to levetiracetam therapy were detected. Conclusions. Intravenous levetiracetam seems to be an effective, safe antiepileptic drug in hospitalised patients, and especially so in those who present an associated comorbidity and/or who are on multiple drug therapy (AU)
Subject(s)
Humans , Anticonvulsants/therapeutic use , Status Epilepticus/drug therapy , Epilepsy/drug therapy , Injections, Intravenous , Retrospective Studies , HospitalizationABSTRACT
INTRODUCTION AND AIMS: Although antiepileptic drugs are usually administered orally, sometimes they must be given intravenously. Levetiracetam is the only one of the new antiepileptic drugs that can be administered intravenously. In this study we report on the use of intravenous levetiracetam in a general hospital, while also evaluating its effectiveness and safety. PATIENTS AND METHODS: A retrospective analysis was conducted of the medical records of all hospital admissions that were treated with intravenous levetiracetam between July 2007 and May 2008. RESULTS: A total of 53 patients were treated with intravenous levetiracetam. Approximately half the patients (47%) had been admitted to neurology, followed by neurosurgery (21%) and oncology (9%). The mean age was 52.2 years (range: 9-87 years) and 40% were females. Seizures were symptomatic in 81% of cases and the most common aetiologies were strokes (40%) and brain tumours (33%). The most frequent presenting symptoms were repeated epileptic seizures (47.2%) and epileptic status (26.4%). Overall, control of seizures was achieved in 87% of patients. No severe side-effects that could be attributed to levetiracetam therapy were detected. CONCLUSIONS: Intravenous levetiracetam seems to be an effective, safe antiepileptic drug in hospitalised patients, and especially so in those who present an associated comorbidity and/or who are on multiple drug therapy.
Subject(s)
Anticonvulsants/administration & dosage , Epilepsy/drug therapy , Piracetam/analogs & derivatives , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Hospitals, General , Humans , Infusions, Intravenous , Levetiracetam , Male , Middle Aged , Piracetam/administration & dosage , Retrospective Studies , Young AdultSubject(s)
Anti-Obesity Agents/adverse effects , Piperidines/adverse effects , Pyrazoles/adverse effects , Sleep Wake Disorders/chemically induced , Adult , Anti-Obesity Agents/therapeutic use , Female , Humans , Obesity/drug therapy , Piperidines/therapeutic use , Pyrazoles/therapeutic use , Receptor, Cannabinoid, CB1/antagonists & inhibitors , RimonabantABSTRACT
No disponible
